Access

Velphoro is accessible and affordable for most patients1,2

MEDICARE PART D

For patients who qualify for the Extra Help low-income subsidy (LIS) and/or are on Medicaid

  • Most patients pay ≤$11.20 per monthly prescription*2
    • No annual deductible3
    • A majority of these patients will have a $0 copay1
    • Direct eligible patients to enroll online at SSA.gov, where they can fill out and submit an application

 

For patients on Medicare Part D Standard

  • With a household income between 150% and 450% of the federal poverty limit, up to $135,000 for a family of four4
  • Patients with out-of-pocket costs of >$50 will be automatically referred to the Patient Assistance Program (PAP)† 
    • Fill out the PAP application provided by your Velphoro Access Solutions Case Manager and obtain the appropriate signatures

 

For patients new to dialysis who have a Medicare application pending within 90 days

  • Velphoro Bridge Program provides up to 90 days of Velphoro at no cost
    • Call Velphoro Access Solutions at 1-877-774-6756

COMMERCIAL INSURANCE

Patients with commercial insurance and copay, coinsurance, or a deductible

  • Velphoro Copay Savings Program: Most patients will pay $0 for Velphoro1
    • Copay savings are automatic; no card required‡

 

Assistance for eligible patients

  • With a household income between 150% and 450% of the federal poverty limit, up to $135,000 for a family of four4
  • Patients with out-of-pocket costs of >$50 will be automatically referred to the Patient Assistance Program (PAP)†
    • Fill out PAP application provided by your Velphoro Access Solutions Case Manager and obtain the appropriate signatures

Starting new patients on Velphoro is easy with
Velphoro Access Solutions

  1. Visit the HCP portal to sign up and log in at VelphoroPathways.com. Initiate benefits investigations for patients, track their application status, monitor their benefits, and access all patient programs provided by Fresenius Renal Pharmaceuticals.

    Fresenius Kidney Care: Please continue to access benefits investigation via ePOC.

  2. Download a benefits investigation application and fax back to Velphoro Access Solutions at 1-866-496-8638.

Contact Velphoro Access Solutions

Velphoro Access Solutions representatives are available to answer questions 
from 8 am to 8 pm ET at 1-877-774-6756

 

*The Extra Help LIS benefit is available for patients who have an income of up to 150% of the federal poverty level (FPL) and meet resource limit requirements. All patients eligible for Extra Help receive full Extra Help; the partial LIS benefit has been phased out as of January 1, 2024.2,3

†Patients with commercial insurance may be eligible for PAP program if out-of-pocket costs are deemed too high with savings program. Eligibility requirements apply.

‡Reimbursement options are available for patients using mail-order fulfillment. Through our partnership with RelayHealth, a card is not required for automatic application of savings at all participating in-network pharmacies. A small percentage of independent or out-of-network pharmacies may still require a downloadable copay card, available at VelphoroCoupon.com. Savings realized after application of automatic $0 copay.

References: 1. Data on file. Fresenius Medical Care North America, Waltham, MA. 2. Medicare.gov. Help with drug costs. https://www.medicare.gov/basics/costs/help/drug-costs. Accessed November 9, 2023. 3. Centers for Medicare and Medicaid Services. CMS releases 2024 projected Medicare Part D premium and bid information. https://www.cms.gov/newsroom/fact-sheets/cms-releases-2024-projected-medicare-part-d-premium-and-bid-information. July 31, 2023. Accessed October 5, 2023. 4. Office of the Assistant Secretary for Planning and Evaluation; US Department of Health and Human Services. Poverty guidelines. https://aspe.hhs.gov/topics/poverty-economic-mobility/poverty-guidelines. Accessed March 9, 2023.

INDICATION

Velphoro® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

IMPORTANT SAFETY INFORMATION

  • Velphoro chewable tablets must be administered with meals. Velphoro should be chewed or crushed. Do not swallow whole.
  • Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, following major gastrointestinal (GI) surgery, or with a history of hemochromatosis or other diseases with iron accumulation have not been included in clinical studies with Velphoro. Monitor effect and iron homeostasis in such patients.
  • In a parallel design, fixed-dose study of 6 weeks duration, the most common adverse drug reactions to Velphoro chewable tablets in hemodialysis patients included discolored feces (12%) and diarrhea (6%).
  • Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMG-CoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. For oral medications where a reduction of bioavailability would be clinically significant consider separating of the timing of administration. Consider monitoring clinical responses or blood levels of the concomitant medications.

Velphoro is available by prescription only. For additional important safety information, please see the full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care North America at 1-800-323-5188 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is intended for use by US healthcare professionals only.

Distributed by:
Fresenius Medical Care North America
Waltham, MA 02451

Fresenius Medical Care Renal Pharmaceuticals

© 2024 Fresenius Medical Care. All Rights Reserved. Fresenius Medical Care and the triangle logo are trademarks of Fresenius Medical Care Holdings, Inc. Velphoro is a trademark of Vifor Fresenius Medical Care Renal Pharma Ltd. All other trademarks are the property of their respective owners.

Do Not Sell or Share My Personal Data • Limit the Use of My Sensitive Personal Information • Consumer Health Data Privacy Policy